Bayer cancels asundexian phase III study program https://ift.tt/uXzbnZJ

The decision to stop the study is based on the recommendation by the Independent Data Monitoring Committee (IDMC). IDMC monitoring showed an inferior efficacy of asundexian compared to the control arm of the study.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/Ish6WZx
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Labels

Blog Archive

Recent Posts

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.